Observers of the potency assay used for botulinum toxin were greeted last year with the news that one company had an alternative, non-animal alternative in place. But all was not as it seemed from the press release, and over a year later, information is still lacking.
Get full access to this article
View all access options for this article.
References
1.
BurkeG.S. (1919). The occurrence of Bacillus botulinus in nature. Journal of Bacteriology4, 541–553.
2.
SesardicD., & Gaines DasR. (2009). Botulinum toxin: Applying the 3Rs to product potency testing. NC3Rs15, 1–8.
3.
BallsM. (2010). Replacing the animal testing of botulinum toxin: Time to smooth out the wrinkles. ATLA38, 1–2.
4.
BitzS. (2010). The botulinum neurotoxin LD50 test — problems and solutions. ALTEX27, 114–116.
5.
PickettA. (2011). Comment on “The botulinum neurotoxin LD50 test — problems and solutions”. ALTEX28, 60–61.
6.
FinziE., & WassermanE. (2006). Treatment of depression with botulinum toxin A: A case series. Dermatologic Surgery32, 645–649; discussion 649–650.
7.
OchudloS., BryniarskiP., & OpalaG. (2007). Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism & Related Disorders13, 505–508.
8.
WollmerM.A., de BoerC., KalakN., BeckJ., GötzT., SchmidtT., HodzicM., BayerU., KollmannT., KolleweK., SönmezD., DuntschK., HaugM.D., SchedlowskiM., HatzingerM., DresslerD., BrandS., Holsboer-TrachslerE., & KrugerT.H. (2012). Facing depression with botulinum toxin: A randomized controlled trial. Journal of Psychiatric Research46, 574–581.
9.
BottrillK. (2003). Growing old disgracefully: The cosmetic use of botulinum toxin. ATLA31, 381–391.
10.
AdlerS., BickerG., BigalkeH., BishopC., BlümelJ., DresslerD., FitzgeraldJ., GesslerF., HeuschenH., KegelB., LuchA., MilneC., PickettA., RatschH., RuhdelI., SesardicD., StephensM., StiensG., ThorntonP.D., ThürmerR., VeyM., SpielmannH., GruneB., & LiebschM. (2010). The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. ATLA38, 315–330.
11.
ClarkK. (2008). Refinement and reduction in botulinum toxin testing. In Report on the ICCVAM-NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing. NIH Publication Number 08–6416, p. 24. Research Triangle Park, NC, USA: National Institute of Environmental Health Sciences, National Institutes of Health, US Public Health Service Department of Health and Human Services. Available at: http://iccvam.niehs.nih.gov/docs/biologics-docs/BoNTwkshprept.pdf (Accessed 09.08. 12).
Allergan, Inc. (2011). Allergan Receives FDA Approval for First-of-its-kind, Fully In Vitro, Cell-based Assay for BOTOX® and BOTOX® Cosmetic (onabotulinum-toxinA) [Press release, 24.06.11]. Available at: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=587234 (Accessed 09.08.12).
